Daniel B Longley

List of Publications by Year
in descending order

66 papers	9,912 citations	212478 28 h-index	134545 62 g-index
69 all docs	69 docs citations	69 times ranked	20732 citing authors

#	Article	IF	Citations
1	FLINO: a new method for immunofluorescence bioimage normalization. Bioinformatics, 2022, 38, 520-526.	1.8	12
2	Stratification of chemotherapy-treated stage III colorectal cancer patients using multiplexed imaging and single-cell analysis of T-cell populations. Modern Pathology, 2022, 35, 564-576.	2.9	12
3	An atlas of inter- and intra-tumor heterogeneity of apoptosis competency in colorectal cancer tissue at single-cell resolution. Cell Death and Differentiation, 2022, 29, 806-817.	5.0	15
4	Functional Genomic Identification of Predictors of Sensitivity and Mechanisms of Resistance to Multivalent Second-Generation TRAIL-R2 Agonists. Molecular Cancer Therapeutics, 2022, 21, 594-606.	1.9	1
5	Attenuating Adaptive VEGF-A and IL8 Signaling Restores Durable Tumor Control in AR Antagonistâ€“Treated Prostate Cancers. Molecular Cancer Research, 2022, 20, 841-853.	1.5	3
6	The role of Ubiquitination in Apoptosis and Necroptosis. Cell Death and Differentiation, 2022, 29, 272-284.	5.0	72
7	Enhanced target-specific delivery of docetaxel-loaded nanoparticles using engineered T cell receptors. Nanoscale, 2021, 13, 15010-15020.	2.8	5
8	Development of a protein signature to enable clinical positioning of IAP inhibitors in colorectal cancer. FEBS Journal, 2021, 288, 5374-5388.	2.2	5
9	Therapeutics Targeting the Core Apoptotic Machinery. Cancers, 2021, 13, 2618.	1.7	14
10	Clinical Positioning of the IAP Antagonist Tolinapant (ASTX660) in Colorectal Cancer. Molecular Cancer Therapeutics, 2021, 20, 1627-1639.	1.9	13
11	Antibody therapy in pancreatic cancer: mAb-ye weâ€™re onto something?. Biochimica Et Biophysica Acta: Reviews on Cancer, 2021, 1876, 188557.	3.3	6
12	Patients with mesenchymal tumours and high<i>Fusobacteriales</i>prevalence have worse prognosis in colorectal cancer (CRC). Gut, 2021, , gutjnl-2021-325193.	6.1	23
13	TNF-Î± synergises with IFN-Î³ to induce caspase-8-JAK1/2-STAT1-dependent death of intestinal epithelial cells. Cell Death and Disease, 2021, 12, 864.	2.7	54
14	TRAIL signaling promotes entosis in colorectal cancer. Journal of Cell Biology, 2021, 220, .	2.3	17
15	The pseudo-caspase FLIP(L) regulates cell fate following p53 activation. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 17808-17819.	3.3	18
16	Molecular subtype-specific responses of colon cancer cells to the SMAC mimetic Birinapant. Cell Death and Disease, 2020, 11, 1020.	2.7	15
17	Pevonedistat (MLN4924): mechanism of cell death induction and therapeutic potential in colorectal cancer. Cell Death Discovery, 2020, 6, 61.	2.0	18
18	Controlled coupling of an ultrapotent auristatin warhead to cetuximab yields a next-generation antibody-drug conjugate for EGFR-targeted therapy of KRAS mutant pancreatic cancer. British Journal of Cancer, 2020, 123, 1502-1512.	2.9	14

#	Article	IF	Citations
19	RALB GTPase: a critical regulator of DR5 expression and TRAIL sensitivity in KRAS mutant colorectal cancer. Cell Death and Disease, 2020, 11, 930.	2.7	12
20	Refined construction of antibody-targeted nanoparticles leads to superior antigen binding and enhanced delivery of an entrapped payload to pancreatic cancer cells. Nanoscale, 2020, 12, 11647-11658.	2.8	16
21	DR5-targeted, chemotherapeutic drug-loaded nanoparticles induce apoptosis and tumor regression in pancreatic cancer in vivo models. Journal of Controlled Release, 2020, 324, 610-619.	4.8	18
22	A revised model of <scp>TRAIL</scp> â€R2 <scp>DISC</scp> assembly explains how <scp>FLIP</scp> (L) can inhibit or promote apoptosis. EMBO Reports, 2020, 21, e49254.	2.0	36
23	The Multiple Roles of the IAP Super-family in cancer. , 2020, 214, 107610.		27
24	FLIP(L): the pseudoâ€caspase. FEBS Journal, 2020, 287, 4246-4260.	2.2	22
25	<i>Fusobacterium nucleatum</i> in the Colorectum and Its Association with Cancer Risk and Survival: A Systematic Review and Meta-analysis. Cancer Epidemiology Biomarkers and Prevention, 2020, 29, 539-548.	1.1	77
26	The SCFSkp2 ubiquitin ligase complex modulates TRAIL-R2-induced apoptosis by regulating FLIP(L). Cell Death and Differentiation, 2020, 27, 2726-2741.	5.0	14
27	Heterogeneous responses to low level death receptor activation are explained by random molecular assembly of the Caspase-8 activation platform. PLoS Computational Biology, 2019, 15, e1007374.	1.5	9
28	A Machine Learning Platform to Optimize the Translation of Personalized Network Models to the Clinic. JCO Clinical Cancer Informatics, 2019, 3, 1-17.	1.0	4
29	Repurposing of Cetuximab in antibody-directed chemotherapy-loaded nanoparticles in EGFR therapy-resistant pancreatic tumours. Nanoscale, 2019, 11, 20261-20273.	2.8	37
30	Abstract 382: Development and pre-clinical assessment of a first-in-class small molecule inhibitor of FLIP. Cancer Research, 2019, 79, 382-382.	0.4	2
31	Simulating and predicting cellular and in vivo responses of colon cancer to combined treatment with chemotherapy and IAP antagonist Birinapant/TL32711. Cell Death and Differentiation, 2018, 25, 1952-1966.	5.0	12
32	Transcriptional Subtyping and CD8 Immunohistochemistry Identifies Patients With Stage II and III Colorectal Cancer With Poor Prognosis Who Benefit From Adjuvant Chemotherapy. JCO Precision Oncology, 2018, 2018, 1-15.	1.5	45
33	Cytoplasmic FLIP(S) and nuclear FLIP(L) mediate resistance of castrate-resistant prostate cancer to apoptosis induced by IAP antagonists. Cell Death and Disease, 2018, 9, 1081.	2.7	14
34	<scp>FLIP</scp> as a therapeutic target in cancer. FEBS Journal, 2018, 285, 4104-4123.	2.2	54
35	Epithelialâ€toâ€mesenchymal transition signature assessment in colorectal cancer quantifies tumour stromal content rather than true transition. Journal of Pathology, 2018, 246, 422-426.	2.1	25
36	Cancer-cell intrinsic gene expression signatures overcome intratumoural heterogeneity bias in colorectal cancer patient classification. Nature Communications, 2017, 8, 15657.	5.8	70

#	Article	IF	Citations
37	IHC-based subcellular quantification provides new insights into prognostic relevance of FLIP and procaspase-8 in non-small-cell lung cancer. Cell Death Discovery, 2017, 3, 17050.	2.0	5
38	A Stepwise Integrated Approach to Personalized Risk Predictions in Stage III Colorectal Cancer. Clinical Cancer Research, 2017, 23, 1200-1212.	3.2	21
39	Immune-Derived PD-L1 Gene Expression Defines a Subgroup of Stage II/III Colorectal Cancer Patients with Favorable Prognosis Who May Be Harmed by Adjuvant Chemotherapy. Cancer Immunology Research, 2016, 4, 582-591.	1.6	35
40	Challenging the Cancer Molecular Stratification Dogma: Intratumoral Heterogeneity Undermines Consensus Molecular Subtypes and Potential Diagnostic Value in Colorectal Cancer. Clinical Cancer Research, 2016, 22, 4095-4104.	3.2	135
41	FLIP: A Targetable Mediator of Resistance to Radiation in Nonâ€“Small Cell Lung Cancer. Molecular Cancer Therapeutics, 2016, 15, 2432-2441.	1.9	21
42	PTEN deficiency promotes macrophage infiltration and hypersensitivity of prostate cancer to IAP antagonist/radiation combination therapy. Oncotarget, 2016, 7, 7885-7898.	0.8	33
43	Stratified analysis reveals chemokine-like factor (CKLF) as a potential prognostic marker in the MSI-immune consensus molecular subtype CMS1 of colorectal cancer. Oncotarget, 2016, 7, 36632-36644.	0.8	15
44	Caspase modelling to predict personalised risk in stage III colorectal cancer (CRC) patients.. Journal of Clinical Oncology, 2016, 34, 11592-11592.	0.8	0
45	HDAC Inhibition Overcomes Acute Resistance to MEK Inhibition in <i>BRAF</i>-Mutant Colorectal Cancer by Downregulation of c-FLIPL. Clinical Cancer Research, 2015, 21, 3230-3240.	3.2	53
46	Molecular classification of the invasive front in colorectal cancer.. Journal of Clinical Oncology, 2015, 33, 3573-3573.	0.8	0
47	ADAM17-Dependent c-MET-STAT3 Signaling Mediates Resistance to MEK Inhibitors in KRAS Mutant Colorectal Cancer. Cell Reports, 2014, 7, 1940-1955.	2.9	90
48	AXL Is a Key Regulator of Inherent and Chemotherapy-Induced Invasion and Predicts a Poor Clinical Outcome in Early-Stage Colon Cancer. Clinical Cancer Research, 2014, 20, 164-175.	3.2	95
49	Efficient Drug Delivery and Induction of Apoptosis in Colorectal Tumors Using a Death Receptor 5-Targeted Nanomedicine. Molecular Therapy, 2014, 22, 2083-2092.	3.7	37
50	Enhanced Antitumor Activity of the Photosensitizer <i>meso</i>-Tetra(<i>N</i>-methyl-4-pyridyl) Porphine Tetra Tosylate through Encapsulation in Antibody-Targeted Chitosan/Alginate Nanoparticles. Biomacromolecules, 2013, 14, 302-310.	2.6	72
51	Cancer drug resistance: an evolving paradigm. Nature Reviews Cancer, 2013, 13, 714-726.	12.8	3,667
52	Prognostic and therapeutic relevance of câ€‹<scp>FLIP</scp> in acute myeloid leukaemia. British Journal of Haematology, 2013, 160, 188-198.	1.2	39
53	Elevation of c-FLIP in Castrate-Resistant Prostate Cancer Antagonizes Therapeutic Response to Androgen Receptorâ€“Targeted Therapy. Clinical Cancer Research, 2012, 18, 3822-3833.	3.2	53
54	A Systems Biology Approach Identifies SART1 as a Novel Determinant of Both 5-Fluorouracil and SN38 Drug Resistance in Colorectal Cancer. Molecular Cancer Therapeutics, 2012, 11, 119-131.	1.9	27

#	Article	IF	Citations
55	Vorinostat/SAHA-induced apoptosis in malignant mesothelioma is FLIP/caspase 8-dependent and HR23B-independent. European Journal of Cancer, 2012, 48, 1096-1107.	1.3	39
56	Conatumumab (AMG 655) coated nanoparticles for targeted pro-apoptotic drug delivery. Biomaterials, 2011, 32, 8645-8653.	5.7	62
57	In vitro and in vivo characterisation of a novel c-FLIP-targeted antisense phosphorothioate oligonucleotide. Apoptosis: an International Journal on Programmed Cell Death, 2010, 15, 1435-1443.	2.2	15
58	Prognostic Significance of TRAIL Signaling Molecules in Stage II and III Colorectal Cancer. Clinical Cancer Research, 2010, 16, 3442-3451.	3.2	70
59	Interleukin-8 signaling attenuates TRAIL- and chemotherapy-induced apoptosis through transcriptional regulation of c-FLIP in prostate cancer cells. Molecular Cancer Therapeutics, 2008, 7, 2649-2661.	1.9	86
60	Cellular FLICE-inhibitory protein regulates chemotherapy-induced apoptosis in breast cancer cells. Molecular Cancer Therapeutics, 2007, 6, 1544-1551.	1.9	44
61	Molecular mechanisms of drug resistance in acute myeloid leukaemia. Expert Opinion on Drug Metabolism and Toxicology, 2007, 3, 363-377.	1.5	15
62	c-FLIP: A Key Regulator of Colorectal Cancer Cell Death. Cancer Research, 2007, 67, 5754-5762.	0.4	110
63	Drug resistance, predictive markers and pharmacogenomics in colorectal cancer. Biochimica Et Biophysica Acta: Reviews on Cancer, 2006, 1766, 184-196.	3.3	106
64	Chemotherapy and TRAIL-mediated colon cancer cell death: the roles of p53, TRAIL receptors, and c-FLIP. Molecular Cancer Therapeutics, 2005, 4, 2026-2036.	1.9	140
65	5-Fluorouracil: mechanisms of action and clinical strategies. Nature Reviews Cancer, 2003, 3, 330-338.	12.8	4,015
66	Apoptotic and Necroptotic Mediators are Differentially Expressed in Mucinous and Non-Mucinous Colorectal Cancer. Frontiers in Oncology, 0, 12, .	1.3	0